LUNG CANCER

Second-line platinum plus pemetrexed produced an 11.5-month median OS and 72% disease control after first-line nivolumab/ipilimumab in pleural mesothelioma.

The FDA has granted fast track designation to BH-30643, an oral OMNI-EGFR inhibitor, for advanced EGFR C797S-positive non–small cell lung cancer after a third-generation TKI.

AstraZeneca is discontinuing the phase 3 eVOLVE-Lung02 trial after finding volrustomig plus chemotherapy unlikely to meet its primary end points in metastatic NSCLC.

Trastuzumab deruxtecan improved progression-free survival vs chemoimmunotherapy in the phase 3 DESTINY-Lung04 trial in HER2-mutant NSCLC.

Savolitinib plus osimertinib met PFS and OS end points vs chemotherapy in the phase 3 SAFFRON trial of EGFR-mutated, MET-driven NSCLC.

Zipalertinib plus platinum-based chemotherapy significantly improved progression-free survival at a planned interim analysis of the phase 3 REZILIENT3 trial.

During a live event, Eric K. Singhi, MD, and participants discussed how CNS activity and cumulative toxicity, not guideline listing alone, are shaping frontline treatment selection in ROS1-positive advanced NSCLC.

The FDA has granted breakthrough device designation to Freenome's SimpleScreen Lung, an investigational blood-based test for high-risk lung cancer screening.

City of Hope's Dr Ravi Salgia urges fellow oncologists to refer eligible patients to a new national trial predicting immunotherapy success in NSCLC.

A guide to the biomarkers oncologists should test for in NSCLC, from established drivers like EGFR and ALK to newer targets such as MET exon 14 and HER2.

Ravi Salgia, MD, PhD, explains the goals of IMMUNO-BIOMAP, a phase 2 trial identifying biomarkers to predict immunotherapy response in NSCLC.

City of Hope's Dr Ravi Salgia on what it would truly take to cure stage IV non–small cell lung cancer and where oncology is headed next in the years ahead.

Benjamin Herzberg, MD, discusses unmet needs, immunotherapy sequencing, and referral timing in KRAS-mutant NSCLC.

Jazz moves to drop Zepzelca’s second-line SCLC use after LAGOON misses survival, while first-line maintenance combo remains approved.

During a live event, Millie Das, MD, and participants discussed why the case for adding a CTLA-4 inhibitor in PD-L1–low metastatic NSCLC does not hold uniformly once histology is taken into account.

Real-world data show Enhertu drives strong responses in HER2-mutant NSCLC, including brain metastases, while highlighting ILD risks and dosing insights.

Responses seen in more than half of treatment-naive patients, including those with low PD-L1 expression, in the TROPION-Lung02 study.

Study aims to lift pathological complete response above the roughly 5% seen with chemotherapy alone in resectable disease.

Danny Nguyen, MD, of City of Hope discusses bringing clinical trials to community oncology practices and the latest advances in lung cancer treatment.

Longer follow-up links ivonescimab plus chemo to stronger survival gains in EGFR-mutant NSCLC worldwide, supporting FDA review after TKI failure.

FDA clears zidesamtinib for previously treated ROS1-positive metastatic NSCLC, showing 44% responses, CNS activity, and manageable safety in ARROS-1 trial.

During a live event, Millie Das, MD, and participants discussed how long-term survival data are reshaping first-line treatment selection for patients with PD-L1–negative metastatic non–small cell lung cancer.

TREASURE trial shows adding thoracic radiotherapy to atezolizumab maintenance in ES‑SCLC boosts fatal toxicity without survival gain.

Phase 3 data show TROP2 ADC sac-TMT plus pembrolizumab extends PFS in PD-L1–negative nonsquamous NSCLC, signaling a new first-line option.